Dali Pharmaceutical Stock Forum

Bomin Electronics' decreasing ROCE trend over five years and stagnant sales despite increased capital investment are concerning. The company's reduction in liabilities, possibly making it less efficient at generating ROCE, suggests it's funding more operations with its own money.

Investors may be expecting future growth or cost cutting due to the company's lack of profits and revenue growth. The company's performance over the last five years has resulted in a total loss of 0.9% per year for shareholders.

Dali Pharmaceuticalco.Ltd's high P/S ratio may not be justified due to declining revenue. The market might be overvaluing its potential, risking shareholder disappointment if the ratio aligns with recent negative growth rates.